Submit

Lung Cancer News

FDA GRANTS PRIORITY REVIEW FOR GENENTECH’S CANCER IMMUNOTHERAPY ATEZOLIZUMAB IN SPECIFIC TYPE OF LUNG CANCER

FDA GRANTS PRIORITY REVIEW FOR GENENTECH’S CANCER IMMUNOTHERAPY ATEZOLIZUMAB IN SPECIFIC TYPE OF LUNG CANCER SOUTH SAN FRANCISCO, Calif. – April 10, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has

Fda Grants Genentech’s Alecensa® (Alectinib) Accelerated Approval For People With A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Alecensa® (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have

VIDEO: Exciting New Discoveries About Lung Cancer Research

Doctor at Baptist Medical Center in Winston-Salem are making some exciting discoveries about lung cancer. WXII 12's Kimberly Van Scoy explains.

VIDEO: Surviving Lung Cancer - One Important Thing

Lung cancer is the No. 1 killer of men and women. But you can survive it by doing very very important thing. WXII 12's Kimberly Van Scoy explains.

VIDEO: Early Detection of Lung Cancer

A new study talks of the importance of detecting early signs of lung cancer; Kimberly Van Scoy reports.

Carbonyl Compounds in Breath Could Help Diagnose Lung Cancer - See more at: http://www.cancernetwork.com/lung-cancer/carbonyl-compounds-breath-could-help-diagnose-lung-cancer#sthash.axdJtfvu.dpuf

Six carbonyl compounds in exhaled breath effectively discriminate between lung cancer patients and healthy controls as well as in those with benign pulmonary nodules, according to a new study. This could be used to easily detect the presence of malignancy - See more at:

AstraZeneca lung cancer drug approved as first-line treatment

AstraZeneca lung cancer drug approved as first-line treatment

The U.S. Food and Drug Administration approved AstraZeneca Plc's drug, Iressa, as a first-line treatment for untreated non-small-cell lung cancer

Novel Antibody Increases Squamous NSCLC Patients’ Survival

Novel Antibody Increases Squamous NSCLC Patients’ Survival

In a new study, researchers performed a phase 3 clinical trial to test how combining chemotherapy with immunotherapy improves advanced untreated squamous non-small-cell lung cancer patients’ outcomes.

Valley Hospital researchers say new blood test that detects early stage lung cancer shows promise

Valley Hospital researchers say new blood test that detects early stage lung cancer shows promise

Researchers at The Valley Hospital and a private lab have developed a blood test that they hope will someday help to detect early-stage lung cancer when it’s most treatable, officials said this week.

GuideStar Gold Participant